ATEA PHARMACEUTICALS INC (AVIR) Stock Analyst Ratings
USA - NASDAQ:AVIR - US04683R1068 - Common Stock
3.05 USD
+0.03 (+0.99%)
3.05 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 83% to AVIR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 100.66% above the current price.
AVIR was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about AVIR.
In the previous month the buy percentage consensus was at a similar level.
AVIR was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |
ATEA PHARMACEUTICALS INC / AVIR FAQ
What is the price target for AVIR stock?
8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 100.66% is expected in the next year compared to the current price of 3.05.
Can you provide the consensus rating for ATEA PHARMACEUTICALS INC stock?
The consensus rating for ATEA PHARMACEUTICALS INC (AVIR) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ATEA PHARMACEUTICALS INC (AVIR) stock?
The number of analysts covering ATEA PHARMACEUTICALS INC (AVIR) is 8.